Immune responses to human papillomavirus

Vaccine

Volumn 24, Issue SUPPL. 1, 2006, Pages S16-

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Human papillomavirus; Immune responses; Keratinocyte

Indexed keywords

VIRUS PROTEIN; WART VIRUS VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

CELL CYCLE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; INFLAMMATION; KERATINOCYTE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS INFECTION; WART VIRUS; BIOSYNTHESIS; CROSS REACTION; IMMUNOLOGY; PAPILLOMA VIRUS;

ANTIBODIES, VIRAL; CLINICAL TRIALS; CROSS REACTIONS; HUMANS; IMMUNITY, CELLULAR; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRAL VACCINES;

EID: 33644938245     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.09.002     Document Type: Article

References (62)

1. R. Medzhitov, and C.A. Janeway Jr. Decoding the patterns of self and nonself by the innate immune system Science 296 2002 298 300
2. B.T. Rouse, and S. Suvas Regulatory cells and infectious agents: détentes cordiale and contraire J Immunol 173 2004 2211 2215
3. L.J. McHeyzer-Williams, and M.G. McHeyzer-Williams Antigen-specific memory B cell development Annu Rev Immunol 23 2005 487 513
4. J.C. Sterling, J.N. Skepper, and M.A. Stanley Immunoelectron microscopical localization of human papillomavirus type 16 L1 and E4 proteins in cervical keratinocytes cultured in vivo J Invest Dermatol 100 1993 154 158
5. M.A. Stanley Replication of human papillomaviruses in cell culture Antiviral Res 24 1994 1 15
6. K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sotlar, and T. Nakahara Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers J Virol 77 2003 10186 10201
7. J.D. Oriel Natural history of genital warts Br J Vener Dis 47 1971 1 13
8. N. Coleman, Birley HDL, A.M. Renton, N.F. Hanna, B.K. Ryait, and M. Byrne Immunological events in regressing genital warts Am J Clin Pathol 102 1994 768 774
9. S. Ghim, J. Newsome, J.P. Sundberg, R. Schlegel, and A.B. Jenson Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus Exp Mol Pathol 68 2000 147 151
10. Ho GYF, R. Bierman, L. Beardsley, C.J. Chang, and R.D. Burk Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 338 1998 423 428
11. M. Schiffman, and S.K. Kjaer Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia J Natl Cancer Inst Monogr 31 2003 14 19
12. E.L. Franco, L.L. Villa, J.P. Sobrinho, J.M. Prado, M.C. Rousseau, and M. Désy Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer J Infect Dis 180 1999 1415 1423
13. A.R. Giuliano, R. Harris, R.L. Sedjo, S. Baldwin, D. Roe, and M.R. Papenfuss Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study J Infect Dis 186 2002 462 469
14. D.R. Brown, M.L. Shew, B. Qadadri, N. Neptune, M. Vargas, and W. Tu A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women J Infect Dis 191 2005 182 192
15. A.J. Remmink, Walboomers JMM, Helmerhorst TJM, F.J. Voorhorst, L. Rozendaal, and Risse EKJ The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months Int J Cancer 61 1995 306 311
16. P. Londesborough, L. Ho, G. Terry, J. Cuzick, C. Wheeler, and A. Singer Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities Int J Cancer 69 1996 364 368
17. K.L. Liaw, A.G. Glass, M.M. Manos, C.E. Greer, D.R. Scott, and M. Sherman Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions J Natl Cancer Inst 91 1999 954 960
18. N.F. Schlecht, S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, and R.A. Miyamura Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia J Am Med Assoc 286 2001 3106 3114
19. R.G. Fruchter, M. Maiman, A. Sedlis, L. Bartley, L. Camilien, and C.D. Arrastia Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus Obstet Gynecol 87 1996 338 344
20. J.S.A. Fennema, E.J.C. van Ameijden, R.A. Coutinho, and A.A.R. van den Hoek HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in A/msterdam AIDS 9 1995 1071 1078
21. K.D. Chirgwin, J. Feldman, M. Augenbraun, S. Landesman, and H. Minkoff Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women J Infect Dis 172 1995 235 238
22. A.B. Moscicki, J.H. Ellenberg, S. Farhat, and J. Xu Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type J Infect Dis 190 2004 37 45
23. A.B. Moscicki, J.H. Ellenberg, P. Crowley-Nowick, T.M. Darragh, J. Xu, and S. Fahrat Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents J Infect Dis 190 2004 1413 1421
24. T.S. Kupper, and R.C. Fuhlbrigge Immune surveillance in the skin: mechanisms and clinical consequences Nat Rev Immunol 4 2004 211 222
25. A. Le Bon, and D.F. Tough Links between innate and adaptive immunity via type I interferon Curr Opin Immunol 14 2002 432 436
26. A.N. Theofilopoulos, R. Baccala, B. Beutler, and D.H. Kono Type I interferons (α/β) in immunity and autoimmunity Annu Rev Immunol 23 2005 307 336
27. Y.E. Chang, and L.A. Laimins Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31 J Virol 74 2000 4174 4182
28. M. Nees, J.M. Geoghegan, T. Hyman, S. Frank, L. Miller, and C.D. Woodworth Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes J Virol 75 2001 4283 4296
29. P. Barnard, and N.A. McMillan The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α Virology 259 1999 305 313
30. L.V. Ronco, A.Y. Karpova, M. Vidal, and P.M. Howley Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity Genes Dev 12 1998 2061 2072
31. S.C. Fausch, D.M. Da Silva, M.P. Rudolf, and W.M. Kast Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses J Immunol 169 2002 3242 3249
32. S.C. Fausch, D.M. Da Silva, and W.M. Kast Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine 23 2005 1720 1729
33. A. Kobayashi, R.M. Greenblatt, K. Anastos, H. Minkoff, L.S. Massad, and M. Young Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection Cancer Res 64 2004 6766 6774
34. R. Kirnbauer, N.L. Hubbert, C.M. Wheeler, T.M. Becker, D.R. Lowy, and J.T. Schiller A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16 J Natl Cancer Inst 86 1994 494 499
35. A. Wikström, van Doornum GJJ, Quint WGV, J.T. Schiller, and J. Dillner Identification of human papillomavirus seroconversions J Gen Virol 76 1995 529 539
36. J.J. Carter, G.C. Wipf, M.E. Hagensee, B. McKnight, L.A. Habel, and S.K. Lee Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts J Infect Dis 172 1995 11 18
37. L.L. Villa, Costa RLR, C.A. Petta, R.P. Andrade, K.A. Ault, and A.R. Giuliano Prophylactic quadrivalent human papillomavirus (types 6, 11 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 6 2005 271 278
38. J.W. Kreider, and G.L. Bartlett The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression Adv Cancer Res 35 1981 81 110
39. J.A. Suzich, S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura, and J.A. Bell Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas Proc Natl Acad Sci USA 92 1995 11553 11557
40. J. Dillner The serological response to papillomaviruses Semin Cancer Biol 9 1999 423 430
41. J. Zhou, X.Y. Sun, D.J. Stenzel, and I.H. Frazer Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles Virology 185 1991 251 257
42. R. Kirnbauer, F. Booy, N. Cheng, D.R. Lowy, and J.T. Schiller Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc Natl Acad Sci USA 89 1992 12180 12184
43. M.E. Hagensee, N.H. Olson, T.S. Baker, and D.A. Galloway Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids J Virol 68 1994 4503 4505
44. N.D. Christensen, C.A. Reed, N.M. Cladel, K. Hall, and G.S. Leiserowitz Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6 Virology 224 1996 477 486
45. M.A. Stanley Human papillomavirus vaccines Curr Opin Mol Ther 4 2002 15 22
46. C.D. Harro, Pang YYS, Roden RBS, A. Hildesheim, Z. Wang, and M.J. Reynolds Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine J Natl Cancer Inst 93 2001 284 292
47. T.G. Evans, W. Bonnez, R.C. Rose, S. Koenig, L. Demeter, and J.A. Suzich A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers J Infect Dis 183 2001 1485 1493
48. K.H. Fife, C.M. Wheeler, L.A. Koutsky, E. Barr, D.R. Brown, and M.A. Schiff Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women Vaccine 22 2004 2943 2952
49. K.A. Ault, A.R. Giuliano, R.P. Edwards, G. Tamms, L.L. Kim, and J.F. Smith A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine Vaccine 22 2004 3004 3007
50. W.I. White, S.D. Wilson, W. Bonnez, R.C. Rose, S. Koenig, and J.A. Suzich In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16 J Virol 72 1998 959 964
51. M.D. Yeager, M. Aste-Amezaga, D.R. Brown, M.M. Martin, M.J. Shah, and J.C. Cook Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies Virology 278 2000 570 577
52. Z. Wang, N. Christensen, J.T. Schiller, and J. Dillner A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera J Gen Virol 78 1997 2209 2215
53. N.D. Christensen, R. Kirnbauer, J.T. Schiller, S.J. Ghim, R. Schlegel, and A.B. Jenson Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes Virology 205 1994 329 335
54. T. Giroglou, M. Sapp, C. Lane, C. Fligge, N.D. Christensen, and R.E. Streeck Immunological analyses of human papillomavirus capsids Vaccine 19 2001 1783 1793
55. A.L. Combita, A. Touzé, L. Bousarghin, N.D. Christensen, and P. Coursaget Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses J Virol 76 2002 6480 6486
56. P. Lenz, C.D. Thompson, P.M. Day, S.M. Bacot, D.R. Lowy, and J.T. Schiller Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells Clin Immunol 106 2003 231 237
57. P. Lenz, D.R. Lowy, and J.T. Schiller Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells Eur J Immunol 35 2005 1548 1556
58. P. Öhlschläger, W. Osen, K. Dell, S. Faath, R.L. Garcea, and I. Jochmus Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice J Virol 77 2003 4635 4645
59. R.T. Emeny, C.M. Wheeler, K.U. Jansen, W.C. Hunt, T.M. Fu, and J.F. Smith Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine J Virol 76 2002 7832 7842
60. L.A. Pinto, J. Edwards, P.E. Castle, C.D. Harro, D.R. Lowy, and J.T. Schiller Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles J Infect Dis 188 2003 327 338
61. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, and A. Schuind Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 2004 1757 1765
62. L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, and F.B. Alvarez A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 2002 1645 1651